Minghui Pharmaceutical
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $131M
Overview
Developing targeted small molecule therapies for cancer and metabolic disorders.
OncologyMetabolic
Technology Platform
A structure-based drug design platform utilizing computational modeling and medicinal chemistry to develop selective small molecule inhibitors.
Funding History
1Total raised:$131M
IPO$131M
Opportunities
Potential to develop best-in-class therapies for validated targets in large market indications.
Risk Factors
Clinical risk of failing to show superiority or sufficient efficacy against established competitors in crowded therapeutic areas.
Competitive Landscape
Faces intense competition in both oncology and metabolic disease from large pharma and numerous biotechs, requiring clear differentiation.